Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) has appointed Dr. Navid Z. Khan as Chief Medical Affairs Officer. With over 20 years of experience, Dr. Khan brings extensive expertise in medical affairs, commercial operations, and R&D. He has overseen 40+ development programs and led seven successful product launches in rare neurology and immunology indications.
Most recently at argenx, Dr. Khan headed the Neuromuscular Therapeutic Area, Medical Affairs, where he led four launches of VYVGART® products. His previous roles include leadership positions at Akouos Inc. and Sarepta Therapeutics, where he was instrumental in launching three Duchenne muscular dystrophy therapies and preparing the company's Medical Affairs organization for gene therapy programs.
Positive
- Appointment of highly experienced executive with over 20 years in medical affairs, commercial, and R&D
- Track record of seven successful U.S. and global product launches
- Extensive experience in neurology and immunology, aligning with company's focus on autoimmune diseases
- Strong background in gene therapy programs and rare disease treatments
Negative
- None.
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer.
Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where he led integrated medical strategy and execution for four launches of VYVGART® and VYVGART Hytrulo®, including two for generalized myasthenia gravis (gMG).
“Navid is an exceptional leader with a proven track record of building world-class medical affairs organizations and executing multiple high-impact product launches,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio. “His deep scientific expertise, combined with his ability to connect with patients, physicians, and global stakeholders, will be invaluable as we advance telitacicept and shape our broader autoimmune portfolio.”
“I am thrilled to join Vor Bio at such an exciting time,” said Dr. Khan. “Vor has the potential to transform the treatment of autoimmune diseases with telitacicept and beyond. I look forward to working with the talented team to build a best-in-class medical affairs function that ensures strong scientific exchange, evidence generation, and meaningful engagement with the patient and physician communities worldwide.”
Earlier in his career, Dr. Khan held senior leadership positions at Akouos Inc. and Sarepta Therapeutics, where he played a pivotal role in the launch of three Duchenne muscular dystrophy therapies - EXONDYS 51®, VYONDYS 53®, and AMONDYS 45® - and helped transform Sarepta’s Medical Affairs organization in preparation for a wave of gene therapy programs. He also held roles of increasing responsibility at EMD Millipore over more than a decade, spanning R&D, viral vector and vaccine strategy, and commercial leadership.
Dr. Khan earned his Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell, and his B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding Vor Bio’s potential to transform the treatment of autoimmune diseases with telitacicept and beyond and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
Who is the new Chief Medical Affairs Officer at Vor Bio (VOR)?
What is Dr. Navid Khan's experience in product launches?
What was Dr. Khan's role before joining Vor Bio?
What therapeutic areas has Dr. Khan worked in?
What is Vor Bio's main focus as a company?
